2013

XenoTech Company Halloween

Author: Matt Beck, Marketing Manager Posted: 01 November 2013

Happy Halloween, XenoTech style! Enjoy some pictures from this year's festivities.

Read more

Navigating the Transporter Wave of 2013: A Review of the Seven ITC Publications on Drug Transporters

Author: Greg Loewen, Principal Scientist - Drug Transport Posted: 28 August 2013

The International Transporter Consortium (ITC) issued seven papers in the July 2013 issue of Clinical Pharmacology & Therapeutics. These seven papers summarize the current understanding of transporters as related to possible drug-drug interactions (DDI). Although there is a mountain of research focusing on many aspects of drug transport such as the transport of endogenous compounds, transport regulation, characterizing transporter function, targeting transporters for disease treatment, etc. these papers outline the information most drug development companies need to know to investigate possible DDIs and properly label their compounds to prevent transporter based DDIs. Since the FDA issued the 2006 “Guidance for Industry, Drug Interaction Studies…” which described the in vitro assays suggested to predict possible P-gp related DDIs, the ITC published a white paper in 2010, the EMA issued the draft “Guideline on the Investigation of Drug Interactions” in 2010 and both the FDA and EMA published updated guidelines in 2012. The most recent guidelines described seven transporters that should be studied for possible DDIs, the in vitro assays used to study those transporters and decision trees to help decide if clinical studies were warranted to further elucidate possible DDIs. The seven papers published in July discuss the clinical importance of the MATE transporters, the clinical importance of OATP1B1 and BCRP polymorphisms, the applicability of the decision trees with some examples of compounds approved since the decision trees were published, in vitro methods used to study transporters, intercellular drug concentrations, kinetic parameters in conjunction with translational modeling, and why DDIs at the blood brain barrier are unlikely. A summary of the focus and main points of each of the seven papers can be found by clicking "Read More" below. To view our webinar on the seven papers click here

Read more